Open access · CC-BY
via OpenAlex
Boosting NAD+ with a small molecule that activates NAMPT
Stephen J. Gardell, Meghan E. Hopf, Asima Khan, Mauro Antonio Dispagna, E. Hampton Sessions, Rebecca Falter, Nidhi Kapoor, Jeanne Kaye Brooks, Jeffrey A. Culver, Chris J. Petucci, Chen-Ting Ma, Steven E. Cohen, Jun Tanaka, Emmanuel S. Burgos, Jennifer S. Hirschi
Nature Communications · 2019 · ▲ 169 citations
Abstract
Abstract Pharmacological strategies that boost intracellular NAD + are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD + precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD + . These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD + . Dosing of mice with SBI-797812 elevates liver NAD + . Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD + and realize its associated salutary effects.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41467-019-11078-z
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Gardell, S.J., Hopf, M.E., Khan, A., Dispagna, M.A., Sessions, E.H., Falter, R., Kapoor, N., Brooks, J.K., Culver, J.A., Petucci, C.J., Ma, C., Cohen, S.E., Tanaka, J., Burgos, E.S., Hirschi, J.S., Smith, S.R., Sergienko, E.A., & Pinkerton, A.B. (2019). Boosting NAD+ with a small molecule that activates NAMPT. <em>Nature Communications</em>. https://doi.org/10.1038/s41467-019-11078-z
Vancouver
Gardell SJ, Hopf ME, Khan A, Dispagna MA, Sessions EH, Falter R, et al. Boosting NAD+ with a small molecule that activates NAMPT. Nature Communications. 2019. doi:10.1038/s41467-019-11078-z.
BibTeX
@article{stephen2019Boosti,
title = {Boosting NAD+ with a small molecule that activates NAMPT},
author = {Stephen J. Gardell and Meghan E. Hopf and Asima Khan and Mauro Antonio Dispagna and E. Hampton Sessions and Rebecca Falter and Nidhi Kapoor and Jeanne Kaye Brooks and Jeffrey A. Culver and Chris J. Petucci and Chen-Ting Ma and Steven E. Cohen and Jun Tanaka and Emmanuel S. Burgos and Jennifer S. Hirschi and Steven R. Smith and Eduard A. Sergienko and Anthony B. Pinkerton},
journal = {Nature Communications},
year = {2019},
doi = {10.1038/s41467-019-11078-z},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics 2020
Open access · OA
Potential significance of NAD+ biology translational research in super-aged Japan
The FASEB Journal 2021
Open access · CC-BY
Reduced nicotinamide mononucleotide is a new and potent NAD + precursor in mammalian cells and mice
Nutrients 2022
Open access · CC-BY
Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase Intracellular NAD+ by Generating Dihydronicotinamide Riboside
Cell Metabolism 2017
Open access · OA
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
CNS Neuroscience & Therapeutics 2016
Open access · OA
Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis
PLoS ONE 2012
Open access · CC-BY